You searched for "VEGF"

168 results found

21st Century retinal laser treatment in the anti-VEGF era

In today’s world, macular laser treatment has a vital role in the treatment of diabetic macular oedema (DMO). DMO is one of the most common causes of visual impairment. Despite expensive intravitreal treatment courses of anti-VEGF, many will agree that...

Type 3 CNV and anti-VEGF

The purpose of the study was to determine the differences between aflibercept and ranibizumab in terms of their therapeutic efficacy in the treatment of Type 3 neovascularisation. The authors highlight that the dominant mechanism for Type 3 neovascularisation development is...

Intravitreal dexamethasone in diabetic macular oedema (DMO) - enhancing the response to anti-VEGF in non- or poor responders

This study aimed to describe the outcomes of a switch back from DEXi (dexamethasone implant) to anti-VEGF therapy in eyes that were treated temporarily with DEXi after an initial poor response to anti VEGF. Twenty-three eyes of 17 patients were...

Comparison of retinal pigment epithelium-choroid graft surgery and anti-VEGF therapy in patients with wet AMD

This was a randomised intervention study in wet AMD patients to investigate benefits of free RPE-choroid graft transplantation surgery versus (continuation of) anti-VEGF treatment. Twenty patients who met the inclusion criteria were subdivided into three subgroups, i.e. RPE tears involving...

Effect of syringe-filling technique and risk for endophthalmitis after intravitreal injection of anti-VEGF agents

In this retrospective study the authors compare the risk for post-injection endophthalmitis between different anti-vascular endothelial growth factor (VEGF) agents and syringe preparation technique. This multicentre study included 197,402 injections. The drugs included in this study were three Anti-VEGF agents...

Outcomes at 100 weeks from the LEAVO study of intravitreal anti-VEGF therapies for macular oedema secondary to central retinal vein occlusion

Royal College of Ophthalmologists Annual Congress 2019, Glasgow - First presented and discussed on Monday 20 May 2019, with a further presentation of results during Retina Subspecialty Day on Thursday 23 May 2019. Among patients with macular oedema secondary to...

Evaluation of Optive® in ocular discomfort after anti-VEGF intravitreal injection

In this study the authors prospectively evaluated the efficacy of Optive® eye drops after in full, then abbreviation - intravitreal injection (IVT). Patients naïve to IVT were included in the study. No artificial tear treatment was prescribed after the first...

AOP Academy: Debate on anti-VEGF use Webinar

@14:00 - 15:00 Paris time: @08:00 - 09:00 New York time

Insights in resistant diabetic macular oedema

This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...

Ginko bilboa extract affects hypoxic retinal pigment epithelial cells

Wet age-related macular degeneration (AMD) is characterised by choroidal neovascular membrane (CNVM) formation. It is thought that localised hypoxia within the retina results in overexpression of growth factors such as vascular endothelial growth factor (VEGF), which induces CNVM formation. VEGF...

Retinal pigment epithelium tears

In this paper the authors review the current knowledge of retinal pigment epithelium (RPE) tears. Although rare these can cause loss of visual acuity. They can occur spontaneously in pigment epithelial detachment (PED) due to occult choroidal neovascularisation (CNV), retinal...

Myopic choroidal neovascularisation

This is a review article summarising the latest myopic CNV (choroidal neovascularisation) literature in the clinical experience and management outcomes for recommendation algorithm. The aetiology of the myopic CNV was discussed by the authors under the heading of the heredo-degenerative...